Research strategies for the treatment of biothreats

Current Opinion in Pharmacology

Volumn 5, Issue 5 SPEC.ISS., 2005, Pages 465-472

  Cherwonogrodzky, John W ^a  

^a DEPARTMENT OF NATIONAL DEFENCE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMPICILLIN; ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CEFTAZIDIME; CIDOFOVIR; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERFERON; LEVAMISOLE; MONOCLONAL ANTIBODY; NORFLOXACIN; NUCLEOTIDE DERIVATIVE; PENICILLIN G; PENTOXIFYLLINE; RIBAVIRIN; RIBOZYME; RIFAMPICIN; SAPONIN; STREPTOMYCIN; SULFONAMIDE; THYMUS HORMONE; UNINDEXED DRUG; VACCINIA ANTIBODY; VANCOMYCIN;

ANTHRAX; ANTIBIOTIC RESISTANCE; BACILLUS ANTHRACIS; BACTERIOPHAGE; BIOLOGICAL WARFARE; BRUCELLA; BRUCELLOSIS; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; CHOLERA; COXIELLA BURNETII; FEAR; FRANCISELLA TULARENSIS; HANTAVIRUS; HORSE DISEASE; HUMAN; JUNIN VIRUS; LASSA FEVER; LASSA VIRUS; MEDICAL RESEARCH; MELIOIDOSIS; MICROENCAPSULATION; MINIMUM INHIBITORY CONCENTRATION; NAIRO VIRUS; PLAGUE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; Q FEVER; REVIEW; RIFT VALLEY FEVER BUNYAVIRUS; SMALLPOX; SMALLPOX VIRUS; TERRORISM; THREAT; TULAREMIA; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIBRIO CHOLERAE; VIRUS ENCEPHALITIS; VIRUS HEMORRHAGIC FEVER; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; YERSINIA PESTIS;

EID: 24344444115     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.04.011     Document Type: Review

References (49)

1. C.L. Barrett S.G. Eubank J.P. Smith If smallpox strikes Portland Sci Am 292 2005 54-61
2. A.R. Lulu G.F. Araj M.I. Khateeb M.Y. Mustafa A.R. Yusuf F.F. Fenech Human brucellosis in Kuwait: A prospective study of 400 cases Q J Med 66 1988 39-54
3. T.J. Torok R.V. Tauxe R.P. Wise J.R. Livengood R. Sokolow S. Mauvais K.A. Birkness M.R. Skeels J.M. Horan L.R. Foster A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars JAMA 278 1997 389-395
4. J.B. Woods Antimicrobials for biological warfare agents. Edited by L.E. Lindler, F.J. Lebeda, G.W. Korch. In Biological Weapons Defense, Infectious Diseases and Counterbioterrorism 2005 Humana Press 285-315
5. E.W. Barrow P.C. Bourne W.W. Barrow Functional cloning of Bacillus anthracis dihydrofolate reductase and confirmation of natural resistance to trimethoprim Antimicrob Agents Chemother 48 2004 4643-4649
6. F.M. Thibault E. Hernandez D.R. Vidal M. Girardet J.D. Cavallo Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents J Antimicrob Chemother 54 2004 1134-1138
7. M.T. Kelly F.W. Hickman-Brenner J.J. Farmer III Vibrio. Edited by A. Balows, W.J. Hausler Jr., K.L. Herrmann, H.D. Isenbeg, H.J. Shamomy. In Manual of Clinical Microbiology, 5th edition 1991 ASM Press 384-395
8. T.V. Inglesby T. O'Toole D.A. Henderson J.G. Bartlett M.S. Ascher E. Eitzen A.M. Friedlander J. Gerberding J. Hauer J. Hughes Anthrax as a biological weapon, 2002: Updated recommendations for management JAMA 287 2002 2236-2252
9. F. Fenner D.O. White Medical Virology 1970 Academic Press 257
10. F. Fenner D.O. White Medical Virology 1970 Academic Press 87
11. J.G. Pace D.R. Franz K.A. Mereish W.L. Thompson R.W. Wannamacher Jr. Use of rifampin for prophylaxis and treatment of microcystin intoxication USAMRIID Report 1992 24-28
12. K. Gregory C.M. Mello Immobilization of Escherichia coli cells by use of the antimicrobial peptide cecropin P1 Appl Environ Microbiol 71 2005 1130-1134
13. K. Chen G.W. Sun K.L. Chua Y.-H. Gan Modified virulence of antibiotic-induced Burkholderia pseudomallei filaments Antimicrob Agents Chemother 49 2005 1002-1009
14. K. Grimwood M. To H.R. Rabin D.E. Woods Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations Antimicrob Agents Chemother 33 1989 41-47
15. M. Fridman V. Belakhov L.V. Lee F.-S. Liang C.-H. Wong T. Baasov Dual effect of synthetic aminoglycosides: Antibacterial activity against Bacillus anthracis and inhibition of anthrax lethal factor Angew Chem Int Ed Engl 44 2005 447-452
16. C. Anne S. Turcaud J. Wuancard F. Teffo H. Mendal M.C. Fournie-Zaluski B.P. Roques Development of potent inhibitors of botulinum neurotoxin type B J Med Chem 46 2003 4648-4656
17. C. Sukonpan T. Oost M. Goodnough W. Tepp E.A. Johnson D.H. Rich Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease J Pept Res 63 2004 181-193
18. C. Anne A. Blommaert S. Turcaud A-S. Martin H. Meudal B.P. Roques Thio-derived disulfides as potent inhibitors of botulinum neurotoxin type B: Implications for zinc interaction Bioorg Med Chem 11 2003 4655-4660
19. K.S. Tanaka X.Y. Chen Y. Ichikawa P.C. Tyler R.H. Furneaux SchrammVL: Ricin A- chain inhibitors resembling the oxacarbenium ion transition state Biochemistry 40 2001 6845-6851
20. D. Liu X.Y. Liu D. Robinson C. Burnett C. Jackson L. Seele R.A. Veach S. Downs R.D. Collins D.W. Ballard J. Hawiger Suppression of staphylococcal enterotoxin B-induced toxicity by a nuclear import inhibitor J Biol Chem 279 2004 19239-19246
21. P.L. Boyer T. Imamichi S.G. Sarafianos E. Arnold S.H. Hughes Effects of the delta-67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision J Virol 78 2004 9987-9997
22. R. Volmer J.J. Bajramovic U. Schneider S. Ufano S. Pochet D. Gonzalez-Dunia Mechanism of the antiviral action of 1-beta-D-arabinofuranosylcytosine on Borna disease virus J Vasc Interv Radiol 79 2005 4514-4518
23. B.A. Bunnell R.A. Morgan Gene therapy for infectious diseases Clin Microbiol Rev 11 1998 42-56
24. H. Zhang R. Hanecak V. Brown-Driver R. Azad B. Conklin M.C. Fox K.P. Anderson Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant Antimicrob Agents Chemother 43 1999 347-353
25. E.G. Saravolac M.E. Christopher M.J. Cairns L.-Q. Sun R.M.K. Dale J.P. Wong Recent development in influenza chemotherapy: Are answers in the viral genome? Recent Dev Antiviral Res 2 2003 1-27
26. R.G. Amado R.T. Mitsuyasu J.D. Rosenblatt F.K. Ngok A. Bakker S. Cole N. Chorn L.S. Lin G. Bristol M.P. Boyd Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients Hum Gene Ther 15 2004 251-262
27. J.P. Wong L.P. Nagata M.E. Chistopher A.M. Salazar R.M. Dale Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs Vaccine 23 2005 2266-2268
28. Wong JP: Saravolac D. Sabuda H.B. Levy M. Kende Prophylactic and therapeutic efficacies of poly(IC-LC) against respiratory influenza A virus infection in mice Antimicrob Agents Chemother 39 1995 2574-2576
29. L. Tissi M. Puliti F. Bistoni P. Mosci T.R. Kozel A. Vecchiarelli Glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, inhibits the progression of group B streptococcal arthritis Infect Immun 72 2004 6367-6372
30. T. Kikuchi N. Ohno T. Ohno Maturation of dendritic cells induced by Candida beta-D-glucan Int Immunopharmacol 2 2002 1503-1508
31. Kournikakis B, Simpson ML, Cherwonogrodzky JW: Bacterial and synthetic polysaccharide immunomodulators that enhance general immunity. 2002, United States patent number 6,444,210.
32. D. Dressler H. Bigalke Botulinum toxin type B de novo therapy of cervical dystonia. Frequency of antibody induced therapy failure J Neurol 2005 [Epub ahead of print]
33. A. Casadevall Passive antibody administration (immediate immunity) as a specific defense against biological weapons Emerg Infect Dis 8 2002 833-841
34. A. Casadevall Antibody-based defense strategies against biological weapons ASM News 71 2005 28-33
35. T.L. Furukawa-Stoffer D.C.W. Mah J.W. Cherwonogrodzky R.J. Weselake A novel biological-based assay for the screening of neutralizing antibodies to ricin Hybridoma 18 1999 505-511
36. Stanier Ry: Doudoroff M, Adelberg EA: The microbial world, edn 3. 1970: 397.
37. R. Schuch D. Nelson V.A. Fischetti A bacteriolytic agent that detects and kills Bacillus anthracis Nature 418 2002 884-889
38. N. Mushtaq M.B. Redpath J.P. Luzio P.W. Taylor Prevention and cure of systemic Escherichia coli K1 infection by modification of the bacterial phenotype Antimicrob Agents Chemother 48 2004 1503-1508
39. K. Thiel Old dogma, new tricks - 21st century phage therapy Nat Biotechnol 22 2004 31-36
40. M.D. Mathur S. Vidhani P.L. Mehndiratta Bacteriophage therapy: An alternative to conventional antibiotics J Assoc Physicians India 51 2003 593-596
41. T.R. Desai J.P. Wong Hancock REW W.H. Finlay A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling J Pharm Sci 91 2002 482-491
42. G. Ruan J.K. Ng S.S. Feng Effects of polymer, organic solvent and mixing strength on integrity of proteins and liposomes encapsulated in polymeric microspheres fabricated by the double emulsion process J Microencapsul 21 2004 399-412
43. P. Cirone J.M. Bourgeois F. SHen P.L. Chang Combined immunotherapy and antiangiogenic therapy of cancer with microencapsulated cells Hum Gene Ther 15 2004 945-959
44. J.P. Wong H. Yang K.L. Blasetti G. Schnell J. Conley L.N. Schofield Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection J Control Release 92 2003 265-273
45. P.G. Detilleux B.L. Deyoe N.F. Cheville Penetration and intracellular growth of Brucella abortus in nonphagocytic cells in vitro Infect Immun 58 1990 2320-2328
46. M.K. Mansour S.M. Levitz Fungal mannoproteins: The sweet path to immunodominance ASM News 2003 595-600
47. Cherwonogrodzky JW, Wong JP, Di Ninno VL: Use of virulence factors of pathogens to improve liposomal delivery of therapeutic agents. 2001, United States patent number 6,221,386.
48. Thompsett AR, Brown DR: A functional role for a copper binding prion protein. In Prions and prion diseases - current perspectives. Edited by Telling GC. 2004:171-175.
49. D.A. Shoskes K.D. Thomas E. Gomez Anti-nanobacterial therapy for men with chronic prostates/chronic pelvic pain syndrome and prostatic stones: Preliminary experience J Urol 173 2005 474-477